Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents Limb-Girdle Muscular Dystrophy Type 2E Functional Results (Transcript) [Seeking Alpha]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Seeking Alpha
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents Limb-Girdle Muscular Dystrophy Type 2E Functional Results (Transcript) Sarepta Therapeutics, Inc. (NASDAQ: SRPT Company Participants Ian Estepan - Senior Vice President, Chief of Staff and Corporate Affairs Douglas Ingram - President and Chief Executive Officer Bo Cumbo - Executive Vice President and Chief Commercial Officer Louise Rodino-Klapac - Senior Vice President, Gene Therapy Conference Call Participants Salveen Richter - Goldman Sachs Eileen Maysek - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Aaron Welch - H.C. Wainwright Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Merrill Lynch Ritu Baral - Cowen and Company Christopher Marai - Nomura Instinet Peter Kim - Barclays Vincent Chen - Bernstein Joel Beatty - Citi Research Joseph Schwartz - Leerink Partners LLC Danielle Brill - Piper Jaffray & Co. Tessa Romero - J.P. Morgan Securities Jonathan Wolleben - JMP Securities Timothy Chiang - BTI
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- High Growth Tech Stocks To Watch For Potential Opportunities [Yahoo! Finance]Yahoo! Finance
- High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]Yahoo! Finance
- High Growth Tech And 2 Other Promising Stocks With Strong Potential [Yahoo! Finance]Yahoo! Finance
- SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sell" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
SRPT
Earnings
- 11/6/24 - Beat
SRPT
Sec Filings
- 12/16/24 - Form 4
- 12/12/24 - Form 144
- 12/6/24 - Form 4
- SRPT's page on the SEC website